Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Effect of lovastatin on behavior in children and adults with fragile X syndrome: an open-label study.

American journal of medical genetics. Part A - 1 Nov 2014

Çaku Artuela, Pellerin David, Bouvier Paméla, Riou Emilie, Corbin Francois

Abstract excerpt

Fragile X syndrome (FXS) results from dynamic mutations leading ultimately to the absence of expression of the Fragile X Mental Retardation Protein (FMRP). It is characterized by synaptic upregulated protein synthesis and immature dendritic spines associated with altered brain plasticity and cognitive functions. Recent work in Fmr1 knockout mice has shown that lovastatin, an inhibitor of Ras-ERK1/2, normalized...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Behavior
Share to Child
Share to Fragile X Mental Retardation Protein

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Fragile X Syndrome

Share to Hydroxymethylglutaryl-CoA Reductase Inhibitors

Share to Lovastatin

Share to Treatment Outcome

Share to Young Adult

Source

Identifiers

PMID: 25258112
DOI: 10.1002/ajmg.a.36750

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Effect of lovastatin on behavior in children and adults with fragile X syndrome: an open-label study.PMID 25258112Read ↗

Fragile X syndrome: A review of clinical managementSemantic proximity Read ↗

Fragile X Syndrome: From Molecular Aspect to Clinical Treatment.Semantic proximity Read ↗

The psychiatric presentation of fragile x: evolution of the diagnosis and treatment of the psychiatric comorbidities of fragile X syndrome.Semantic proximity Read ↗

Lovastatin, not simvastatin, corrects core phenotypes in the fragile X mouse modelSemantic proximity Read ↗

Pharmacological management of fragile X syndrome: a systematic review and narrative summary of the current evidence.Semantic proximity Read ↗

Rescue of fragile X syndrome phenotypes in Fmr1 KO mice by a BKCa channel opener molecule.Semantic proximity Read ↗

Lovastatin, not Simvastatin, Corrects Core Phenotypes in the Fragile X Mouse Model.Semantic proximity Read ↗

Neuropsychiatric symptoms of fragile X syndrome: pathophysiology and pharmacotherapy.Semantic proximity Read ↗

Dietary supplementation of omega-3 fatty acids rescues fragile X phenotypes in Fmr1-Ko mice.Semantic proximity Read ↗

Measuring Effectiveness of Treatments in Rare Disorders, Evidence from Clinical Trials in Fragile X SyndromeSemantic proximity Read ↗

Reversal of behavioural phenotype by the cannabinoid-like compound VSN16R in fragile X syndrome mice.Semantic proximity Read ↗

Rescue of fragile X syndrome phenotypes in Fmr1 KO mice by the small-molecule PAK inhibitor FRAX486.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.